Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 225 of 885 entries
View as:

Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT02252172 Org: User:
Start: 02/16/15 End: 10/02/24 Due: 10/02/25

A Study to Assess the Efficacy and Safety of Mebendazole for the Treatment of Helminth Infections in Pediatric Participants

Phase: N/A Priority: Normal
NCT ID: NCT02034162 Org: User:
Start: 12/31/14 End: 09/30/15 Due: 09/30/16

Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene

Phase: N/A Priority: Normal
NCT ID: NCT04671433 Org: User:
Start: 12/04/20 End: 09/30/24 Due: 09/30/25

Bioequivalence Study of Metformin Component of Canagliflozin and Metformin Fixed Dose Combination Immediate Release (IR) Tablet Comparing With Metformin IR Tablet Co-administered With Canagliflozin Tablet in Healthy Fed and Fasted Participants

Phase: N/A Priority: Normal
NCT ID: NCT02220218 Org: User:
Start: 08/31/14 End: 10/31/14 Due: 10/31/15

A Study of Apalutamide in Participants With Severe Hepatic Impairment Compared With Participants With Normal Hepatic Function

Phase: N/A Priority: Normal
NCT ID: NCT04154774 Org: User:
Start: 11/07/19 End: 02/10/25 Due: 02/10/26

A Study to Investigate the Efficacy and Safety of Canagliflozin in Children and Adolescents (>=10 to <18 Years) With Type 2 Diabetes Mellitus

Phase: N/A Priority: Normal
NCT ID: NCT03170518 Org: User:
Start: 07/21/17 End: 09/20/23 Due: 09/20/24

A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic Severely Obese Participants

Phase: N/A Priority: Normal
NCT ID: NCT03486392 Org: User:
Start: 03/26/18 End: 03/08/19 Due: 03/08/20

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01756638 Org: User:
Start: 06/06/12 End: 10/17/14 Due: 10/17/15

A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT03234972 Org: User:
Start: 11/30/17 End: 02/27/24 Due: 02/27/25

Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-55375515 in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT02623491 Org: User:
Start: 11/30/15 End: 09/30/16 Due: 09/30/17

A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants

Phase: N/A Priority: Normal
NCT ID: NCT02077803 Org: User:
Start: 03/31/14 End: 07/31/14 Due: 07/31/15

Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for Suicide

Phase: N/A Priority: Normal
NCT ID: NCT03185819 Org: User:
Start: 10/05/17 End: 03/31/23 Due: 03/31/24

A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42847922 in Participants With Insomnia Disorder

Phase: N/A Priority: Normal
NCT ID: NCT03375203 Org: User:
Start: 11/23/17 End: 04/03/19 Due: 04/03/20

A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy

Phase: N/A Priority: Normal
NCT ID: NCT03321526 Org: User:
Start: 12/12/17 End: 06/27/19 Due: 06/27/20

A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

Phase: N/A Priority: Normal
NCT ID: NCT03434041 Org: User:
Start: 05/25/18 End: 04/13/21 Due: 04/13/22

A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression

Phase: N/A Priority: Normal
NCT ID: NCT04599855 Org: User:
Start: 11/04/20 End: 01/31/24 Due: 01/31/25

A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT04722146 Org: User:
Start: 03/12/21 End: 04/07/27 Due: 04/07/28

A Pharmacokinetic Study in Healthy Participants to Assess the Pharmacokinetics and Safety of a Supratherapeutic Dose of PCI-32765 (Ibrutinib) Capsule and Solution Formulations Administered With Food

Phase: N/A Priority: Normal
NCT ID: NCT01969266 Org: User:
Start: 10/31/13 End: 11/30/13 Due: 11/30/14

A Study of JNJ-53718678 in Participants With Hepatic Impairment

Phase: N/A Priority: Normal
NCT ID: NCT04332523 Org: User:
Start: 08/17/20 End: 03/16/22 Due: 03/16/23

CANVAS - CANagliflozin cardioVascular Assessment Study

Phase: N/A Priority: Normal
NCT ID: NCT01032629 Org: User:
Start: 12/09/09 End: 02/22/17 Due: 02/22/18

A Safety and Efficacy Study of JNJ26489112 in Patients With Treatment-Resistant Major Depressive Disorder

Phase: N/A Priority: Normal
NCT ID: NCT01114698 Org: User:
Start: 03/31/11 End: 02/29/12 Due: 02/28/13

A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis

Phase: N/A Priority: Normal
NCT ID: NCT04951622 Org: User:
Start: 07/15/21 End: 04/17/26 Due: 04/17/27

Study to Assess the Relative Bioavailability of Orally Administered JNJ-42756493 Tablet Versus JNJ-42756493 Capsule in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT02231489 Org: User:
Start: 09/30/14 End: 11/30/14 Due: 11/30/15

A Safety and Tolerability Study of JNJ-54861911 in Participants With Early Alzheimer's Disease

Phase: N/A Priority: Normal
NCT ID: NCT02260674 Org: User:
Start: 11/30/14 End: 06/30/16 Due: 06/30/17

A Double-blind Study to Assess the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Participants Who Are Assessed to be at Imminent Risk for Suicide

Phase: N/A Priority: Normal
NCT ID: NCT02133001 Org: User:
Start: 05/23/14 End: 02/01/16 Due: 02/01/17